Taranabant - Weight Loss Medication information

What is Taranabant?

     Taranabant is the generic name (currently at time of writing no trademarked name available)
of a medication that is currently being developed by Merck®. It is being designed similarly to that of Rimonabant (Acomplia®) in fighting the battle against obesity. It is currently going under stage 3 tests and so far indications appear that it will be submitted to the FDA sometime in 2008 for approval. Earlier in 2007, the FDA did not approve of Rimonabant for the use of an anti obesity medication. There still remains some hope that it may at sometime with future study be approved as an anti obesity drug or possibly to fight some other ailments but for now it has not been approved for use in the USA, but has been approved for use in several European countries and other countries around the world.
     There is much hope around Taranabant that it will provide for Americans a medication that will help them fight off obesity. With obesity growing seemingly out of control, not to mention other health hazards that come with obesity it is with much anticipation that this medication be accepted. In January 2008, a trial 3 update was released. It indicated that taranabant does indeed help people loose weight verses the people who where taking a placebo. Even at lower dosages Taranabant is seemingly working well at removing excess weight off of individuals. As with all medications there are some risks of side effects to some of its takers. What this study found was that with increased dosages, the amount of anxiety, potential gastrointestinal issues, psychiatric matters, nausea and vomiting tended to go up with some of its patients.
     Later studies in March of 2008 indicated that once again the tests were promising, leading to "significant weight loss" and the doses given are much less that of rimonabant. What remains to be seen are how the rest of the final studies go, any other potential side effects and how medical doctors perceive this information. Then if it does go to the FDA, It will be then awaited to see how they take into consideration all of the information and studies on Taranabant. The FDA has in the past been given a bit of a bad reputation for possibly passing medications before enough study was done on them. But with the denial on rimonabant, it will be interesting to see how they (if it goes that far) view and explain their conclusions. As future developments are released, it is our goal to have that information displayed on this website.

Disclaimer: Acomplia® (Rimonabant) is the registered trademark of Sanofi-Aventis. This site is not in any way associated or affiliated with them. Any information found here is provided for general informational purposes only and is not meant to take the place of the advice provided by your own physician or other medical professional. You should not use any of the information found here to diagnose or treat a health issue or disease or to prescribe any medication. Always seek medical advice from a medical doctor. Please Read Entire Disclaimer.